## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.2% below STRENGTH zone (3.0-6.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($238.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Resmed CFO Sandercock sells $244,160 in stock By Investing.com**
- Source: Investing.com Nigeria | 20251202T223000 | Neutral | Relevance: 100%
- Resmed CFO Brett Sandercock sold 1,000 shares of RESMED INC (NASDAQ:RMD) common stock for $244,160 on December 1, 2025. Following the sale, executed under a Rule 10b5-1 plan, Sandercock directly owns 87,495 shares. The company, which has raised its dividend for 14 consecutive years and boasts strong financial health, recently reported strong Q4 2025 revenues of $1.35 billion, exceeding analyst forecasts.

**2. Neuberger Berman Group LLC Purchases 22,431 Shares of ResMed Inc. $RMD**
- Source: MarketBeat | 20251130T122155 | Bullish | Relevance: 99%
- Neuberger Berman Group LLC significantly increased its stake in ResMed Inc. by 71.2% during the second quarter, adding 22,431 shares to its holdings, which are now valued at approximately $13.91 million. The article details ResMed's strong Q2 performance, beating EPS and revenue expectations, and highlights current analyst ratings as "Moderate Buy" with a target price of $297.45. It also covers recent insider sales and ResMed's announced quarterly dividend.

**3. 1,187,798 Shares in ResMed Inc. $RMD Acquired by Norges Bank**
- Source: MarketBeat | 20251202T113256 | Somewhat-Bullish | Relevance: 99%
- Norges Bank acquired a significant new stake of 1,187,798 shares in ResMed Inc. (NYSE:RMD) during Q2, valued at approximately $306.45 million. This acquisition represents about 0.81% of the company, highlighting institutional confidence in the medical equipment provider. ResMed recently reported strong Q3 earnings, exceeding revenue and EPS estimates, and has a consensus "Moderate Buy" rating from analysts.

**4. Russell Investments Group Ltd. Buys 8,601 Shares of ResMed Inc. $RMD**
- Source: MarketBeat | 20251201T111414 | Somewhat-Bullish | Relevance: 99%
- Russell Investments Group Ltd. increased its stake in ResMed Inc. by 10.1% in Q2, acquiring 8,601 additional shares to hold a total of 93,789 shares valued at $24.18 million. Despite this institutional buying, ResMed insiders, including CEO Michael J. Farrell, have recently been net sellers of the stock. The company reported strong Q3 earnings, beating analyst estimates, and announced a quarterly dividend of $0.60 per share.

**5. Resmed CFO Sandercock sells $244,160 in stock**
- Source: Investing.com | 20251202T162900 | Somewhat-Bullish | Relevance: 99%
- Resmed CFO Brett Sandercock sold 1,000 shares of RMD stock for $244,160 on December 1, 2025, through a Rule 10b5-1 plan. Despite the sale, the stock has risen, and InvestingPro analysis suggests ResMed is undervalued with "GREAT" financial health. The company also reported strong Q4 2025 revenue of $1.35 billion, surpassing analyst forecasts.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($9.51M) |
| Sells | 14 ($4.85M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $4.9M in recent transactions.
2. Elevated short interest (8.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 20.9x stretched relative to 10% growth. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $36.7B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 20.9 |
| Current P/E | 23.0 |
| YoY Growth | 10.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.5% to -2.2% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. MACD histogram positive (1.23), confirming momentum. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.18% (CS: 33) | Weak |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | 1.23 | Bullish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 0.961x | Below |
| vs SMA200 | 0.994x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $250.85
- **Stop Loss:** $238.07 (5.1% risk)
- **Target:** $263.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 78
- **Position Value:** $19,566.30
- **Portfolio %:** 19.57%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*